- Home
- ATEX vs MREO Comparison
ATEX vs MREO Comparison
Compare ATEX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- MREO
- Stock Information
- Founded
- ATEX 1997
- MREO 2015
- Country
- ATEX United States
- MREO United Kingdom
- Employees
- ATEX N/A
- MREO N/A
- Industry
- ATEX Telecommunications Equipment
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- MREO Health Care
- Exchange
- ATEX Nasdaq
- MREO Nasdaq
- Market Cap
- ATEX 623.7M
- MREO 577.6M
- IPO Year
- ATEX N/A
- MREO N/A
- Fundamental
- Price
- ATEX $33.72
- MREO $3.72
- Analyst Decision
- ATEX Strong Buy
- MREO Strong Buy
- Analyst Count
- ATEX 2
- MREO 4
- Target Price
- ATEX $68.00
- MREO $7.50
- AVG Volume (30 Days)
- ATEX 110.1K
- MREO 804.7K
- Earning Date
- ATEX 11-13-2024
- MREO 11-12-2024
- Dividend Yield
- ATEX N/A
- MREO N/A
- EPS Growth
- ATEX N/A
- MREO N/A
- EPS
- ATEX N/A
- MREO N/A
- Revenue
- ATEX $5,607,000.00
- MREO $1,000,000.00
- Revenue This Year
- ATEX $58.60
- MREO $16.39
- Revenue Next Year
- ATEX $5.40
- MREO $9.44
- P/E Ratio
- ATEX N/A
- MREO N/A
- Revenue Growth
- ATEX 97.01
- MREO N/A
- 52 Week Low
- ATEX $29.12
- MREO $1.86
- 52 Week High
- ATEX $42.41
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- ATEX 50.28
- MREO 41.37
- Support Level
- ATEX $32.55
- MREO $3.18
- Resistance Level
- ATEX $34.51
- MREO $4.40
- Average True Range (ATR)
- ATEX 1.18
- MREO 0.23
- MACD
- ATEX 0.07
- MREO -0.04
- Stochastic Oscillator
- ATEX 60.27
- MREO 44.67
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).